EASD 2016:降低HbA1c,能减少血管并发症风险

2016-09-20 Seven L 译 MedSci原创

EASD 2016公布的寿命仿真模型数据显示,对于2型糖尿病和心血管疾病的成年患者,HbA1c每下降1%,微血管和大血管并发症的相对风险将降低。 来自牛津大学的Samiul A. Mostafa博士和同事们对5717例2型糖尿病和已知心血管疾病患者进行了研究,患这来自于TECOS试验(平均年龄66岁;女性占28%;85%的患者为白人;2型糖尿病病程11年;11%的患者为吸烟者)。 使用

EASD 2016公布的寿命仿真模型数据显示,对于2型糖尿病和心血管疾病的成年患者,HbA1c每下降1%,微血管和大血管并发症的相对风险将降低。

来自牛津大学的Samiul A. Mostafa博士和同事们对5717例2型糖尿病和已知心血管疾病患者进行了研究,患这来自于TECOS试验(平均年龄66岁;女性占28%;85%的患者为白人;2型糖尿病病程11年;11%的患者为吸烟者)。

使用英国糖尿病前瞻性研究结果模型版本2.0,研究者对五种不同HbA1c值(10%、9%、8%、7%、6%)患者的微血管和大血管并发症风险进行了评估;其他风险值保持不变。

对于HbA1c为10%的患者,心肌梗死的10年估计中位风险为22.3% (95% CI, 21.9-22.6);随着HbA1c每下降1%,10年心肌梗死风险逐渐降低(P-trend < .001)。HbA1c值为9%、8%、7%、6%的患者,其HbA1c值每下降1%,累积RR分别下降4.6%、9.3%、15.1%、20.2%。

对于脑卒中、单眼失明、截肢和死亡率,研究者观察到类似的趋势。根据模型,HbA1c从10%下降到7%,卒中、截肢、单眼失明和全因死亡率RR分别减少19.6%、52.3%、37.1%和3.9%。

预防2型糖尿病并发症还需要控制好其他危险因素;尤其是收缩压和低密度脂蛋白胆固醇。在以后还需要更多的研究验证本结果。

原始出处:


Mostafa S, et al. Poster #1137. Presented at: 52nd EASD Annual Meeting; Sept. 12-16, 2016; Munich.

HbA1c lowering models predict reductions in microvascular, macrovascular complications
.Healio.September 19, 2016

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2015905, encodeId=1d6120159051c, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Dec 22 07:10:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690607, encodeId=a843169060e4b, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Sat Oct 01 10:10:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757736, encodeId=34b11e577360a, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Wed Apr 19 03:10:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135468, encodeId=7ff9135468c0, content=谢谢指点迷津, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Mon Sep 26 16:31:00 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534098, encodeId=eaca153409861, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Thu Sep 22 13:10:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545342, encodeId=825b1545342c0, content=<a href='/topic/show?id=a803896303f' target=_blank style='color:#2F92EE;'>#血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89630, encryptionId=a803896303f, topicName=血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67913724176, createdName=ms3892185887221420, createdTime=Thu Sep 22 13:10:00 CST 2016, time=2016-09-22, status=1, ipAttribution=)]
    2016-12-22 Smile2680
  2. [GetPortalCommentsPageByObjectIdResponse(id=2015905, encodeId=1d6120159051c, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Dec 22 07:10:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690607, encodeId=a843169060e4b, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Sat Oct 01 10:10:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757736, encodeId=34b11e577360a, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Wed Apr 19 03:10:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135468, encodeId=7ff9135468c0, content=谢谢指点迷津, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Mon Sep 26 16:31:00 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534098, encodeId=eaca153409861, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Thu Sep 22 13:10:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545342, encodeId=825b1545342c0, content=<a href='/topic/show?id=a803896303f' target=_blank style='color:#2F92EE;'>#血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89630, encryptionId=a803896303f, topicName=血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67913724176, createdName=ms3892185887221420, createdTime=Thu Sep 22 13:10:00 CST 2016, time=2016-09-22, status=1, ipAttribution=)]
    2016-10-01 okhuali
  3. [GetPortalCommentsPageByObjectIdResponse(id=2015905, encodeId=1d6120159051c, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Dec 22 07:10:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690607, encodeId=a843169060e4b, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Sat Oct 01 10:10:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757736, encodeId=34b11e577360a, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Wed Apr 19 03:10:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135468, encodeId=7ff9135468c0, content=谢谢指点迷津, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Mon Sep 26 16:31:00 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534098, encodeId=eaca153409861, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Thu Sep 22 13:10:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545342, encodeId=825b1545342c0, content=<a href='/topic/show?id=a803896303f' target=_blank style='color:#2F92EE;'>#血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89630, encryptionId=a803896303f, topicName=血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67913724176, createdName=ms3892185887221420, createdTime=Thu Sep 22 13:10:00 CST 2016, time=2016-09-22, status=1, ipAttribution=)]
    2017-04-19 丁鹏鹏
  4. [GetPortalCommentsPageByObjectIdResponse(id=2015905, encodeId=1d6120159051c, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Dec 22 07:10:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690607, encodeId=a843169060e4b, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Sat Oct 01 10:10:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757736, encodeId=34b11e577360a, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Wed Apr 19 03:10:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135468, encodeId=7ff9135468c0, content=谢谢指点迷津, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Mon Sep 26 16:31:00 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534098, encodeId=eaca153409861, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Thu Sep 22 13:10:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545342, encodeId=825b1545342c0, content=<a href='/topic/show?id=a803896303f' target=_blank style='color:#2F92EE;'>#血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89630, encryptionId=a803896303f, topicName=血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67913724176, createdName=ms3892185887221420, createdTime=Thu Sep 22 13:10:00 CST 2016, time=2016-09-22, status=1, ipAttribution=)]
    2016-09-26 1e0ece0dm09(暂无匿称)

    谢谢指点迷津

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2015905, encodeId=1d6120159051c, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Dec 22 07:10:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690607, encodeId=a843169060e4b, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Sat Oct 01 10:10:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757736, encodeId=34b11e577360a, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Wed Apr 19 03:10:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135468, encodeId=7ff9135468c0, content=谢谢指点迷津, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Mon Sep 26 16:31:00 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534098, encodeId=eaca153409861, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Thu Sep 22 13:10:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545342, encodeId=825b1545342c0, content=<a href='/topic/show?id=a803896303f' target=_blank style='color:#2F92EE;'>#血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89630, encryptionId=a803896303f, topicName=血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67913724176, createdName=ms3892185887221420, createdTime=Thu Sep 22 13:10:00 CST 2016, time=2016-09-22, status=1, ipAttribution=)]
    2016-09-22 qilu_qi
  6. [GetPortalCommentsPageByObjectIdResponse(id=2015905, encodeId=1d6120159051c, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Dec 22 07:10:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690607, encodeId=a843169060e4b, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Sat Oct 01 10:10:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757736, encodeId=34b11e577360a, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Wed Apr 19 03:10:00 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135468, encodeId=7ff9135468c0, content=谢谢指点迷津, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Mon Sep 26 16:31:00 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534098, encodeId=eaca153409861, content=<a href='/topic/show?id=576e643634' target=_blank style='color:#2F92EE;'>#EASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6436, encryptionId=576e643634, topicName=EASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21f812527653, createdName=qilu_qi, createdTime=Thu Sep 22 13:10:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545342, encodeId=825b1545342c0, content=<a href='/topic/show?id=a803896303f' target=_blank style='color:#2F92EE;'>#血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89630, encryptionId=a803896303f, topicName=血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67913724176, createdName=ms3892185887221420, createdTime=Thu Sep 22 13:10:00 CST 2016, time=2016-09-22, status=1, ipAttribution=)]

相关资讯

Stroke:仅根据HbA1c诊断糖尿病不能预测卒中不良预后

背景:推荐应用糖化血红蛋白(HbA1c)来诊断糖尿病,但根据新标准初诊为糖尿病(NDDM)是否与卒中预后相关尚不清楚。研究者旨在探讨缺血性脑卒中的预后与按新标准诊断为NDDM的相关性。方法: 纳入中国急性卒中血糖调节异常研究中,无糖尿病病史的缺血性脑卒中患者进行调查分析。。NDDM定义为空腹血糖≥7 7.0 mmol/L,口服葡萄糖耐量试验2h时≥11.1 mmol/L,或糖化血红蛋白≥6.5%,

Diabetes Obes Metab:短期补充维生素D能否影响HbA1c?

先前有研究表明25(OH)D含量与2型糖尿病和冠状动脉存在风险呈负相关,但并没有估计两者间的因果联系。研究者对糖尿病风险增加的人群进行了一项研究,探究短期内服用维生素D补充剂对心血管代谢疾病的预后影响。该双盲安慰剂对照随机试验共纳入了340名2型糖尿病风险增加成年人(非糖尿病的高血糖症或糖尿病风险评分阳性),将其随机分为维生素D2 100,000 IU或维生素D3 100,000 IU和安慰剂组。

Diabetes Care:有无血管疾病的2型糖尿病患者HbA1c与心血管事件的关系

目标:2型糖尿病患者的血管事件与血糖控制不良相关,但是血管疾病的存在可能影响两者之间的关系。研究人员评估血糖控制(HbA1c)与有无血管疾病的2型糖尿病患者新发心血管事件及其死亡率的关系。研究设计和方法:在SMART的研究中选取2型糖尿病患者1687名,应用Cox比例风险模型,对有无血管疾病进行分层分析HbA1c与心血管事件(包括心肌梗死,卒中以及血管性死亡)发生之间的关系。结果:随访时间的中位数

J Altern Complement Med:糖尿病患者福音,芦荟能降血糖!

根据最近的一项荟萃分析,口服芦荟可以降低前驱糖尿病和2型糖尿病患者的空腹血糖和HbA1c。利福尼亚特拉维斯空军基地格兰特空军医疗中心的William R. Dick药学博士和同事们分析了九项研究的数据,评估口服芦荟的摄入对前驱糖尿病和2型糖尿病患者的空腹血糖和HbA1c的影响。9项研究涉及空腹血糖数据(N = 283),5项研究涉及HbA1c数据N = 89)。3项研究涉及芦荟汁,1项研究使用芦荟

AJRCCM:持续气道正压通气可改善伴阻塞性睡眠呼吸暂停的2型糖尿病患者的血糖控制

据发表于American Journal of Respiratory and Critical Care Medicine的一项研究显示,对于血压难以控制的伴阻塞性睡眠呼吸暂停的2型糖尿病患者来说,持续气道正压通气治疗6个月可明显改善患者的血糖控制和胰岛素抵抗状况。

Diabetes Care:HbA1c和腰围是预测减肥术后糖尿病缓解程度的指标

目的 糖尿病患者行减肥手术的标准是BMI≥35kg/m2及血糖控制欠佳。然而,仅以BMI不能预测糖尿病的缓解程度,因此需要进一步明确能预测糖尿病缓解程度的指标。 研究设计及研究方法 从瑞典肥胖患者研究和两个随机对照研究中,一共挑选727名糖尿病患者入组,其中415名患者接受减肥手术治疗,而312名患者接受药物治疗。而减肥手术治疗组又分为胃减容术组和胃转流术组。 结果: